Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the joints, leading to pain, swelling, and joint deformity. Among the potential targets for RA treatment is Bruton's tyrosine kinase (BTK), which plays a crucial role in B-cell signaling and contributes to the pathogenesis of RA.In present work this software was explored for pharmacophore optimization of the pyrrolo- pyrimidine nucleus for antirheumatoid activity.This research provided valuable insights into the structural features essential for BTK inhibition and paves the way for the design and development of novel anti-rheumatic agents targeting BTK in RA.